Authors Posts by Joshua Rodriguez

Joshua Rodriguez

2633 POSTS 445 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

Michael Kors Holdings Ltd KORS Stock News

Michael Kors Holdings Ltd (NYSE: KORS) is having an incredibly strong day in the market today, and the spike is only growing larger. Ultimately, the gains are being caused by a rumor, which we’ll get to later. Nonetheless, as soon as the stock started spiking, our partners at Trade Ideas alerted us to the trend. At the moment (10:45), KORS is trading at $38.39 per share after a gain of $0.92 per share (2.46%) thus far today.





KORS Gains On Takeover Rumors

As mentioned above, Michael Kors is having an incredible day in the market today following a rumor that surfaced on social media. The rumor is that the company will soon be acquired. While the rumor doesn’t suggest who the buyer is, it does suggest that the company will be taken over at a price of $53 per share in an all-cash transaction.




It’s important to keep in mind that we see these types of rumors all the time in the market, and in most cases, they prove to be invalid. It doesn’t look like this one is going to happen. Considering that the rumor started on social media and no reputable source is associated with it, chances are that this one is false. So, if you’re going to trade on the news, trade with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on KORS. In particular, we’re interested to see if there is any validity to the rumor mentioned above. While we don’t think there is, anything can happen in the market. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to break the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

Twitter Inc TWTR Stock News

Twitter Inc (NYSE: TWTR) is having an incredible day in the market today, and for good reason. Investors seem to have finally gotten what they’ve been waiting for in terms of earnings and user growth. As a result, the stock is headed skyward, prompting our partners at Trade Ideas to alert us to the movement. At the moment (10:27), TWTR is trading at $16.26 per share after a gain of $1.58 per share or 10.80% thus far today.





TWTR Beats On Earnings And Produces User Growth

As mentioned above, Twitter is having a strong day in the market today, and for good reason. The company released its earnings report, finally giving investors what they’ve been waiting for. Ultimately, that’s user growth. Through the report, investors learned that TWTR pulled in average monthly active users in the amount of 328 million in the first quarter. That represents a 6% incrfease on a year over year basis and a gain of 9 million monthly active users on a quarter over quarter basis. Considering that user growth has been a primary source of concern, this is overwhelmingly positive news.




On the earnings side of the coin, TWTR produced adjusted earnings per share in the amount of $0.11. This came in above the FactSet consensus estimate of $0.02. Revenue also proved to be a big hit, coming in at $548 million. The FactSet consensus on Twitter revenue was $517 million.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TWTR. In particular, we’re interested to see if the company can keep the growth coming. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to break the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 317
Alnylam Pharmaceuticals, Inc. ALNY Stock News

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is having a pretty strong start to the trading session today, and for good reason. The company announced that it has reached an agreement with the FDA surrounding a planned Phase III clinical trial. As a result, investors got excited and the stock is finding its way upward. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:45), ALNY is trading at $51.86 per share after a gain of $0.51 per share or 0.98% thus far today.





ALNY Gains On Agreement With FDA Surrounding Planned Phase III Clinical Trial

As mentioned above, Alnylam Pharmaceuticals is having a strong day in the market today after it announced an agreement with the FDA centered around a planned Phase III clinical trial for inclisiran, a treatment that ALNY is working closely with The Medicines Company (MDCO) to develop. The trial is expected to support the submission of a New Drug Application surrounding the atherosclerotic cardiovascular disease (ASCVD) treatment. In a statement, John M. Maraganore, Ph.D., CEO at ALNY had the following to offer…




The Medicines Company’s agreement with the FDA supports a clear path forward for further inclisirin development and regulatory review. Indeed, we’re pleased with the excellent progress made by our colleagues at The Medicines Company to advance this potential, innovative medicine to patients in need, and we intend to fully support them in their efforts… Moreover, we believe the planned development path for inclisiran positions this promising potential medicine to contribute meaningfully to our alnylam 2020 goals.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both ALNY and MDCO. In particular, we’re interested in following the progression surrounding inclisiran. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 328
Aratana Therapeutics Inc PETX Stock News

Aratana Therapeutics Inc (NASDAQ: PETX) is having a pretty strong start to the trading session today, and for good reason. The company provided a positive update with regard to Entyce(R), exciting investors and sending the stock upward. Of course, our partners at Trade Ideas were the first to alert us to the movement. Currently (9:32), PETX is trading at $6.20 per share after a gain of $0.16 per share or 2.65% thus far today.





PETX Provides Positive Update

As mentioned above, Aratana Therapeutics is having a strong start to the day after announcing updates with regard to Entyce. The company said that it has met with the US FDA center for veterinary medicine regarding the proposed manufacturing transfer of entyce. They believe that it is in agreement with CVM on how to proceed.




If the PETX submission is approved, the company believes that the treatment will become commercially available by fall of 2017. The company also said that it intends a resubmission in the coming weeks in order to get the process rolling.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PETX. In particular, we’re interested in following the company through the process of making entyce commercially available. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 552
3D Systems Corporation DDD Stock News

3D Systems Corporation (NYSE: DDD) is having a relatively strong start to the day in the pre-market, and for good reason. The company announced plans to collaborate with United Therapeutics Corporation (NASDAQ: UTHR). As a result, investors got excited, leading to gains in the stock and prompting our partners at Trade Ideas to inform us of the gains. At the moment (8:52), DDD is trading at $15.81 per share after a gain of $0.22 per share (1.41%) thus far today.





DDD Gains On Partnership With UTHR

As mentioned above, 3D systems is having a strong day in the market today after announcing that it has entered into a partnership with United Therapeutics. The two companies will be working together to develop solid-organ scaffolds for human transplants. The first part of the collaboration will be work on lung scaffolds. In a statement, Vyomesh Joshi, CEO at DDD, had the following to offer:




As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting… We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the caliber of United Therapeutics to provide healthcare solutions of the future.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both DDD and UTHR. In particular, we’re interested in following their collaboration and hoping for success in their plans. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 227
MediciNova, Inc. MNOV Stock News

MediciNova, Inc. (NASDAQ: MNOV) is having an incredible time in the pre-market hours this morning, and for good reason. The company recently released interim exploratory clinical outcomes with regard to a key treatment, and the data was positive. As a result, investor excitement ensued and the stock started gaining in a big way. This prompted our partners at Trade Ideas to alert us to the movement. At the moment (8:51), MNOV is trading at $6.75 per share after a gain of $1.18 per share or 21.18% thus far today.





MNOV Reports Positive Data

As mentioned above, MediciNova is having an incredibly strong start to the day today after presenting exploratory interim data from the company’s ongoing clinical trial of MN-166 (ibudilast). The medication is designed for the treatment of amyotrophic lateral sclerosis. The interim data showed that survival rate after open-label period was significantly higher in the group of patients who completed the entire treatment than it was for the group of patients who withdrew prior to the open-label period. In a statement, Dr. Benjamin Brooks, Director at Carolinas HeathCare System’s Neuromuscular/ALS-MDA Center had the following to say with regard to the MNOV data…




We are encouraged by the interim data thus far from this exploratory analysis. This sub-group analysis suggests that the bulbar-onset ALS patient may be a target for future clinical trials because we found no change in lower motor neuron ALS burden on the Brisbane-Sydney UMN LMN ALS Burden Scale in this subgroup, but further analysis is needed as perhaps this is not the only responsive group but only the group that we can see in a clinical trial designed as we did.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNOV. In particular, we’re interested in following the company through the development and eventually commercialization of MN-166. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 339
Akebia Therapeutics Inc AKBA Stock News

Akebia Therapeutics Inc (NASDAQ: AKBA) is having an incredibly strong start to the day in the pre-market hours this morning, and for good reason. A key pact the company is part of is being expanded, and this means that more money is coming into the company. Of course, this led to investor excitement, causing the stock to head upward and prompting our partners at Trade Ideas to alert us to the movement. At the moment (8:30), AKBA is trading at $12.00 per share after a gain of $2.63 per share or 28.07% thus far today.





AKBA Gains On Extended Patent

As mentioned above, Akebia Therapeutics is having an incredibly strong start to the trading session today after it was announced that a key pact has been expanded. The pact is with Otsuka Pharmaceuticals surrounding vadadustat. According to the press release, AKBA has agreed to give Otsuka the rights to their anemia pill in exchange for $73 million upfront and up to $792 million in development funding and milestone payments. In a statement, John Butler, CEO at AKBA, had the following to offer…




We now have a signle, strong collaborator for the two largest markets, the U.S. and Europe. This simplifies governance and decision making, maximizing the efficiency of our global phase 3 development program and ultimately the commercialization of vadadustat.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AKBA. In particular, we’re watching the ongoing development of vadadustat and how this expanded pact will equate to revenue for the company. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 344
Orexigen Therapeutics, Inc. OREX Stock News

Orexigen Therapeutics, Inc. (NASDAQ: OREX) is having an incredible day in the market today, and for good reason. The company announced a submission for a new drug in Canada. Of course, this led to investor excitement, causing gains in the stock and prompting our partners at Trade Ideas to alert us to the trends. At the moment (11:27), OREX is trading at $3.14 per share after a gain of $0.16 per share or 5.23% thus far today.





OREX Announces New Drug Submission

As mentioned above, Orexigen is having an incredibly strong start to the trading session today after announcing a new drug submission. The company has submitted Contrave(C) for regulatory approval in Canada. Of course, after submission, investors wait months before an approval or denial decision. Nonetheless, this is causing quite a bit of excitement in the investing community and pushing the stock upward, and for good reason. Considering all of the recent news and data surrounding Contrave, there’s a good chance of approval here.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching OREX incredibly closely. In particular, we’re interested in following the new drug submission and hopefully approval of Contrave ahead. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 289
Can Fite Biopharma Ltd (ADR) CANF Stock News

Can Fite Biopharma Ltd (ADR) (NYSE: CANF) is having an incredibly strong morning in the market this morning after announcing that it has received approval for a key Phase III trial. This of course led to excitement among investors, causing a frenzy and pushing the stock upward. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:00), CANF is trading at $1.95 per share after a gain of $0.13 per share or 7.14% thus far today.





CANF Receives Approval For Key Phase III Clinical Trial

As mentioned above, Can Fite Biopharma is having an incredibly strong day in the market today after announcing that the Barzilai Medical Center’s Institutional Review Board has approved the Phase III ACRobat trial protocol. As a result, patient enrollment will begin soon in Ashkelon, Israel. In a statement, Dr. Pnina Fishman, CEO at CANF, had the following to offer…




Piclidenson has demonstrated its safety profile in over 1,000 patients and prior clinical data show its potential to be as effective, or more effective, than MTX in treating rheumatoid arthritis. Our ACRobat trial is powered to demonstrate Piclidenoson’s potential as a first line therapy and superior alternative to MTX, which unfortunately can have several side effects for patients who need a long-term treatment solution.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CANF. In particular, we’ll be following the Phase II trial surrounding Picilidenson and are excited for the results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 275

Paratek Pharmaceuticals Inc (NASDAQ: PRTK) is having a pretty strong start to the trading session today after announcing that it has signed a collaboration agreement. Of course, this excited investors, leading to gains in the value of the stock and prompting our partners at Trade Ideas to alert us to the move. At the moment (10:45), PRTK is trading at $21.65 per share after a gain of $0.25 per share or 1.17% thus far today.





PRTK Enters Collaboration Agreement

As mentioned above, Paratek Pharmaceuticals is up in the market this morning after announcing that it has entered into a collaboration agreement with Zai Lab. The agreement surrounds the development and commercialization of omadacycline for patients in China. According to the agreement, PRTK has granted Zai Lab an exclusive license to develop, manufacture and commercialize omadacycline for the greater China Territory. The company well receive $7.5 million in upfront payments and will be eligible for development, regulatory, and commercial milestone payments. In a statement, Michael Bigham, Chairman and CEO at PRTK, had the following to offer…




Our successful Phase 3 efficacy studies in both skin infections and pneumonia demonstrate the potential of omadacycline to be a promising new therapeutic option for the treatment of patients with serous bacterial infections… This agreement with Zai Lab further validates that potential, and represents an exciting step toward making omadacycline available to the many patients in the greater China territory where there is a proven need for a new, effective, well tolerated, IV and once-daily oral, broad-spectrum antibiotic, particularly when resistance is of concern.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PRTK. In particular, we’re following ongoing work surrounding omadacycline as the treatment seems to be overwhelmingly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4649
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...